NADPH Oxidase-derived ROS Contributes to Upregulation of TRPC6 Expression in Puromycin Aminonucleoside-induced Podocyte InjuryWang Z.1,* · Wei X.1,* · Zhang Y.1 · Ma X.2 · Li B.3 · Zhang S.1 · Du P.1 · Zhang X.1 · Yi F.1
1Department of Pharmacology, Shandong University School of Medicine, Jinan,2Department of Physiology, Shandong University School of Medicine, Jinan,3Ultrastructure Laboratory, Shandong University School of Medicine, Jinan,*Co-first authors, equally contributed to this work
Fan Yi, Ph.D
Department of Pharmacology
Shandong University School of Medicine
44#, Wenhua Xi Road, Jinan, Shandong, 250012 (P.R. China)
Tel. +86-0531-88382616, Fax: +86-0531-88382616, E-Mail email@example.com
Do you have an account?
Recent studies have demonstrated upregulation of transient receptor potential cation channel 6 (TRPC6) contributes to podocyte injury in acquired forms of proteinuric kidney diseases, such as focal segmental glomerulosclerosis (FSGS). However, under these pathophysiological conditions, the mechanisms of regulation of TRPC6 expression and activity remain unknown. The present study tested the hypothesis that NADPH oxidase-mediated redox signaling importantly participates in the development of podocyte injury by regulation of TRPC6 expression and activity. Injection of puromycin aminonucleoside (PAN) to rats produced severe proteinuria and mimics the lesions of FSGS. Podocyte effacement, NADPH oxidase subunit NOX4 expression, enzyme activity and TRPC6 expression were significant increased in glomeruli from PAN nephrosis rats. Inhibition of NADPH oxidase activity by apocynin ameliorated proteinuria and podocyte effacement and reduced TRPC6 expression. In in vitro study, PAN significantly increased NOX4 and TRPC6 expression levels in cultured podocytes. This increased TRPC6 expression was attenuated by apocynin or siRNA-NOX4. Our results provide direct evidence for the first time that NADPH oxidase-derived reactive oxygen species (ROS) is one of critical components of a signal transduction pathway that links PAN nephrosis to TRPC6-mediated Ca2+ signaling.
© 2009 S. Karger AG, Basel
Article / Publication Details
Copyright / Drug Dosage / DisclaimerCopyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher or, in the case of photocopying, direct payment of a specified fee to the Copyright Clearance Center.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.